We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
RNS Number : 0840J
Clinigen Group plc
18 December 2020
18 December 2020
Appointment of Nominated Adviser and Joint Broker
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global pharmaceutical and services company, has appointed Numis Securities Ltd as Nominated Adviser and Joint Broker with immediate effect. RBC Capital Markets will continue to act as the Group's Joint Broker.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495 010 Shaun Chilton, Group Chief Executive Officer Nick Keher, Group Chief Financial Officer Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260 & Joint Broker 1000 James Black / Freddie Barnfield / Garry Levin Tel: +44 (0) 20 7653 RBC Capital Markets - Joint Broker 4000 Marcus Jackson / Elliot Thomas Instinctif Partners Tel: +44 (0) 20 7457 2020 Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage Email: clinigen@instinctif.com
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPGPGQPPUPUGRM
(END) Dow Jones Newswires
December 18, 2020 02:00 ET (07:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions